Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

Dentsply International / Equity Bottom-Up

<ul><li>Dentsply Sirona delivered mixed results for Q1 2025, highlighting both progress and challenges across its operations.</li><li>The company faced a 7.7% decline in total revenue compared to the previous year, with organic sales down by 4.4%.</li><li>This decline included a significant negative impact from Byte, which was responsible for a 4% drop, illustrating ongoing challenges in the Company's orthodontics segment.</li></ul>

Dentsply Sirona delivered mixed results for Q1 2025, highlighting both progress and challenges across its operations.The company faced a 7.7% decline in total revenue compared to the previous year, with organic sales down by 4.4%.This decline included a significant negative impact from Byte, which was responsible for a 4% drop, illustrating ongoing challenges in the Company's orthodontics segment.

Dentsply Sirona: DS Core & Digital Connectivity to Boost Customer Retention & Loyalty Over The Long Term!

<ul><li>DENTSPLY SIRONA's fourth-quarter and full-year 2024 earnings report reflects a mixed performance amid ongoing challenges and strategic repositioning.</li><li>On the positive side, the company experienced growth in several areas, including a 13% uplift in imaging and a 7% increase in Wellspect sales.</li><li>In Europe, DENTSPLY SIRONA achieved a 2% organic sales growth, supported by significant momentum in Germany and a 20% year-on-year growth in the SureSmile business.</li></ul>

DENTSPLY SIRONA's fourth-quarter and full-year 2024 earnings report reflects a mixed performance amid ongoing challenges and strategic repositioning.On the positive side, the company experienced growth in several areas, including a 13% uplift in imaging and a 7% increase in Wellspect sales.In Europe, DENTSPLY SIRONA achieved a 2% organic sales growth, supported by significant momentum in Germany and a 20% year-on-year growth in the SureSmile business.

Global Healthcare Analyst

Tina Banerjee

<ul>
<li>
<a href="https://www.smartkarma.com/entities/mani-inc" target="_blank" data-smartkarma-citation="entities:6534:1" rel="noopener">Mani Inc (7730 JP)</a> Q1FY25 revenue rose 8% YoY, mainly driven by surgical and eyeless needles segments, and favorable foreign exchange. However, profitability declined year-over-year.</li>
<li>Despite the underperformance of dental segment, management reiterated FY25 guidance. Dental segment contributes more than 30% of total revenue.</li>
<li>Mani shares plunged 20% since it published its Q1 results. Investors should avoid Mani due to its uncertain revenue outlook and deteriorating profitability in short-term.</li>
</ul>



Mani Inc (7730 JP) Q1FY25 revenue rose 8% YoY, mainly driven by surgical and eyeless needles segments, and favorable foreign exchange. However, profitability declined year-over-year.
Despite the underperformance of dental segment, management reiterated FY25 guidance. Dental segment contributes more than 30% of total revenue.
Mani shares plunged 20% since it published its Q1 results. Investors should avoid Mani due to its uncertain revenue outlook and deteriorating profitability in short-term.


Mani Inc (7730 JP): Dental Loosing Shine In China; Margins Eroding; FY25 Guidance Reiterated

<ul><li>Dentsply Sirona's third quarter 2024 results present a nuanced picture, with both challenges and advancements across its business segments.</li><li>The company reported $951 million in revenue, marking a modest increase of 0.5% on a reported basis and a 1.3% rise on an organic basis year-over-year.</li><li>This growth was primarily driven by timing impacts, as distributors made advance purchases in the Essential Dental Solutions (EDS) segment due to the upcoming U.S. ERP deployment.</li></ul>

Dentsply Sirona's third quarter 2024 results present a nuanced picture, with both challenges and advancements across its business segments.The company reported $951 million in revenue, marking a modest increase of 0.5% on a reported basis and a 1.3% rise on an organic basis year-over-year.This growth was primarily driven by timing impacts, as distributors made advance purchases in the Essential Dental Solutions (EDS) segment due to the upcoming U.S. ERP deployment.

Dentsply Sirona: SureSmile Realignment: The Bold Strategy to Conquer the Aligner Market! - Major Drivers

<ul><li>DENTSPLY SIRONA Inc., a major player in the dental solutions and technologies market, reported a mixed second quarter performance for the fiscal year 2024.</li><li>The company faced notable challenges, including a decline in revenue to $984 million, primarily impacted by lower sales in its Connected Technology Solutions (CTS) segment.</li><li>This was attributed to ongoing pressures in the capital equipment market, partially influenced by macroeconomic conditions, pricing degradation, and suboptimal performance in key markets.</li></ul>

DENTSPLY SIRONA Inc., a major player in the dental solutions and technologies market, reported a mixed second quarter performance for the fiscal year 2024.The company faced notable challenges, including a decline in revenue to $984 million, primarily impacted by lower sales in its Connected Technology Solutions (CTS) segment.This was attributed to ongoing pressures in the capital equipment market, partially influenced by macroeconomic conditions, pricing degradation, and suboptimal performance in key markets.

DENTSPLY SIRONA Inc.: An Insight Into Dental Industry Trends & Transformation Initiatives! - Major Drivers

United States

DENTSPLY International Inc. manufactures and distributes dental supplies on a worldwide basis.  The Company's products include dental prosthetics, endodontic instruments, dental sealants, ultrasonic scalers, dental x-ray equipment, and intraoral cameras.  DENTSPLY also provides impression materials, orthodontic appliances, and dental operatory software systems, and other dental products.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Dentsply International (XRAY US)

Dentsply Sirona: DS Core & Digital Connectivity to Boost Customer Retention & Loyalty Over The Long Term!

Dentsply Sirona delivered mixed results for Q1 2025, highlighting both progress and challenges across its operations. The company faced a 7.7%...

Baptista Research

Dentsply Sirona’s Plan: Merging Tech

DENTSPLY SIRONA's fourth-quarter and full-year 2024 earnings report reflects a mixed performance amid ongoing challenges and strategic...

Baptista Research

Mani Inc (7730 JP): Dental Loosing Shine In China; Margins Eroding; FY25 Guidance Reiterated

Mani's Q1FY25 revenue was up 8% YoY driven by surgical and eyeless needles, but profitability declined. Dental segment continued to underperform....

Tina Banerjee

Dentsply Sirona: SureSmile Realignment: The Bold Strategy to Conquer the Aligner Market! - Major Drivers

Dentsply Sirona's third quarter 2024 results present a nuanced picture, with both challenges and advancements across its business segments. The...

Baptista Research

DENTSPLY SIRONA Inc.: An Insight Into Dental Industry Trends & Transformation Initiatives! - Major Drivers

DENTSPLY SIRONA Inc., a major player in the dental solutions and technologies market, reported a mixed second quarter performance for the fiscal...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Dentsply Sirona: DS Core & Digital Connectivity to Boost Customer Retention & Loyalty Over The Long Term!

Dentsply Sirona delivered mixed results for Q1 2025, highlighting both progress and challenges across its operations. The company faced a 7.7%...

Baptista Research

Dentsply Sirona’s Plan: Merging Tech

DENTSPLY SIRONA's fourth-quarter and full-year 2024 earnings report reflects a mixed performance amid ongoing challenges and strategic...

Baptista Research

Mani Inc (7730 JP): Dental Loosing Shine In China; Margins Eroding; FY25 Guidance Reiterated

​Mani's Q1FY25 revenue was up 8% YoY driven by surgical and eyeless needles, but profitability declined. Dental segment continued to underperform....

Tina Banerjee

Dentsply Sirona: SureSmile Realignment: The Bold Strategy to Conquer the Aligner Market! - Major Drivers

Dentsply Sirona's third quarter 2024 results present a nuanced picture, with both challenges and advancements across its business segments. The...

Baptista Research

DENTSPLY SIRONA Inc.: An Insight Into Dental Industry Trends & Transformation Initiatives! - Major Drivers

DENTSPLY SIRONA Inc., a major player in the dental solutions and technologies market, reported a mixed second quarter performance for the fiscal...

Baptista Research

Mani's Q1FY25 revenue was up 8% YoY driven by surgical and eyeless needles, but profitability declined. Dental segment continued to underperform....